+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Respiratory Syncytial Virus Treatment Market - Global Forecast 2025-2030- Product Image
Human Respiratory Syncytial Virus Treatment Market - Global Forecast 2025-2030- Product Image
Sale

Human Respiratory Syncytial Virus Treatment Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6133822
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The human respiratory syncytial virus (RSV) market is rapidly evolving amidst urgent clinical needs and transformational scientific progress. Senior decision-makers face a shifting landscape—driven by emerging therapies, regulatory activity, and supply chain pressures—requiring targeted strategies for effective investment and innovation.

Market Snapshot: Human Respiratory Syncytial Virus (RSV) Treatment

The RSV treatment market is undergoing significant change, fueled by the introduction of novel antiviral agents, advanced monoclonal antibodies, and promising vaccine candidates. Technology advancements in molecular biology and antibody engineering are facilitating new therapeutic modalities and broader preventative approaches. The sector’s landscape is further shaped by regulatory milestones and ongoing clinical evaluation of both live attenuated and recombinant vaccines. As a result, providers and policymakers are closely watching the market for emerging best practices in patient care and resource allocation.

Scope & Segmentation

This executive report delivers a detailed analysis of the RSV therapeutics landscape across the following key market segments:

  • Product Types: Antiviral drugs (RNA interference, small molecule); Monoclonal antibodies (fully human, humanized); Vaccines (live attenuated, recombinant)
  • Indications: Prophylactic use (elderly, high-risk infants, immunocompromised), Therapeutic intervention (mild, moderate, severe)
  • Age Groups: Adult (18–64 years), Geriatric (65+ years), Pediatric (2–12 years, under 2 years)
  • End Users: Clinics (long-term care, outpatient), Hospitals (private, public), Research institutes (government, private)
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy
  • Regional Coverage: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Technological Approaches: Advanced antibody engineering, RNA interference, small molecule antivirals, live attenuated and recombinant vaccine development
  • Leading Companies: AstraZeneca PLC; Pfizer Inc.; GlaxoSmithKline plc; Moderna, Inc.; Johnson & Johnson; Sanofi S.A.; Merck & Co., Inc.; Novavax, Inc.; Bavarian Nordic A/S; Gilead Sciences, Inc.

Key Takeaways

  • Recent scientific advances are catalyzing a shift from supportive care to targeted RSV interventions, with a new generation of RNA interference therapies and engineered monoclonal antibodies setting performance benchmarks.
  • Industry collaborations and joint ventures between biopharmaceutical companies, academic institutions, and public health agencies are supporting robust product pipelines and expediting development timelines.
  • Clinical adoption is rising amidst greater appreciation of age- and risk-segmented approaches, while end-user needs vary across clinics, hospitals, and research institutes, shaping market access priorities.
  • Regional trends highlight rapidly strengthening healthcare infrastructures in Asia-Pacific, evolving reimbursement frameworks in the Americas, and efforts to bolster local manufacturing in EMEA regions.
  • Integration of real-world evidence, adaptive regulatory pathways, and proactive supply chain management is becoming essential for maintaining competitive positioning and expanding patient access.

Tariff Impact: Navigating the 2025 U.S. Supply Chain and Pricing Environment

In 2025, new United States tariffs on pharmaceutical imports are driving additional cost pressures and complexities across the RSV supply chain. The increased landed cost for active pharmaceutical ingredients and finished products stimulates shifts toward localized contract manufacturing and renegotiated supply agreements. Industry participants are mitigating the impact through proactive cost classification, free trade zone utilization, and supply-chain diversification. These measures are essential for preserving access and managing downstream pricing and reimbursement changes for advanced antivirals, monoclonal antibodies, and vaccines.

Methodology & Data Sources

This analysis applies a rigorous methodology combining in-depth interviews with clinicians, virologists, and payers, paired with comprehensive secondary research from peer-reviewed sources, clinical trial registries, and regulatory filings. Data triangulation ensures consistency and reliability across all findings.

Why This Report Matters

  • Enables executive decision-makers to anticipate emerging market shifts and competitive developments in RSV therapeutics.
  • Delivers targeted strategic recommendations to enhance portfolio resilience, optimize regulatory engagement, and safeguard supply chain continuity.
  • Equips stakeholders with actionable insights for investment, commercialization, and long-term planning in a rapidly changing sector.

Conclusion

Senior leaders benefit from a clear, analytic view of the RSV market’s drivers and challenges. With integrated recommendations and thorough segmentation, this report supports effective decision-making throughout the lifecycle of RSV therapy development and adoption.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of long-acting monoclonal antibody prophylaxis for high-risk infant populations beyond neonatal phase
5.2. Integration of maternal RSV immunization programs to curb infant hospitalization rates
5.3. Development of small molecule RSV inhibitors targeting viral fusion protein sites resistant to existing therapies
5.4. Rising adoption of combination antiviral and immune-modulatory treatment regimens in severe RSV cases
5.5. Growth in point-of-care diagnostics enabling early RSV detection and timely therapeutic intervention
5.6. Pipeline acceleration of next generation live attenuated RSV vaccines with enhanced mucosal immunity profiles
5.7. Strategic collaborations between biotech firms and academic institutions for RSV drug discovery and clinical trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Respiratory Syncytial Virus Treatment Market, by Product Type
8.1. Introduction
8.2. Antiviral Drugs
8.2.1. Rna Interference
8.2.2. Small Molecule
8.3. Monoclonal Antibodies
8.3.1. Fully Human
8.3.2. Humanized
8.4. Vaccines
8.4.1. Live Attenuated
8.4.2. Recombinant
9. Human Respiratory Syncytial Virus Treatment Market, by Indication
9.1. Introduction
9.2. Prophylactic Use
9.2.1. Elderly
9.2.2. High-Risk Infants
9.2.3. Immunocompromised
9.3. Therapeutic Use
9.3.1. Mild
9.3.2. Moderate
9.3.3. Severe
10. Human Respiratory Syncytial Virus Treatment Market, by Age Group
10.1. Introduction
10.2. Adult
10.2.1. 18 To 64 Years
10.3. Geriatric
10.3.1. 65 Years And Above
10.4. Pediatric
10.4.1. 2 To 12 Years
10.4.2. Under 2 Years
11. Human Respiratory Syncytial Virus Treatment Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Long-Term Care Facilities
11.2.2. Outpatient Clinics
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
11.4. Research Institutes
11.4.1. Government Research Institutes
11.4.2. Private Research Institutes
12. Human Respiratory Syncytial Virus Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Human Respiratory Syncytial Virus Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Human Respiratory Syncytial Virus Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Human Respiratory Syncytial Virus Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AstraZeneca PLC
16.3.2. Pfizer Inc.
16.3.3. GlaxoSmithKline plc
16.3.4. Moderna, Inc.
16.3.5. Johnson & Johnson
16.3.6. Sanofi S.A.
16.3.7. Merck & Co., Inc.
16.3.8. Novavax, Inc.
16.3.9. Bavarian Nordic A/S
16.3.10. Gilead Sciences, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET: RESEARCHAI
FIGURE 26. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HIGH-RISK INFANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HIGH-RISK INFANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 18 TO 64 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 18 TO 64 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 65 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 65 YEARS AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 2 TO 12 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 2 TO 12 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY UNDER 2 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY UNDER 2 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 181. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 184. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 185. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 186. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 187. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 188. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 189. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 192. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 193. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 194. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 195. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 196. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 197. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 198. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 199. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 200. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 201. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 202. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 203. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 206. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 207. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 208. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 209. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 210. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 211. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 216. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 217. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 218. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 219. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 220. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 221. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 224. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 225. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 226. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 227. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 228. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 229. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 230. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 231. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 232. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 233. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 234. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 235. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 238. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 239. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 240. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 241. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 242. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 243. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL HUMAN RESP

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Human Respiratory Syncytial Virus Treatment market report include:
  • AstraZeneca PLC
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Moderna, Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Bavarian Nordic A/S
  • Gilead Sciences, Inc.

Related Topics

Related Reports

Respiratory Syncytial Virus Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Respiratory Syncytial Virus Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 82 Pages
  • Global
From
Respiratory Syncytial Virus Therapeutic Drugs Market - Global Forecast 2025-2030 - Product Image

Respiratory Syncytial Virus Therapeutic Drugs Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutics Market Report 2025 - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.